.png "Biogen Inc (NASDAQ: BIIB)")
Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biogen Inc (NASDAQ: BIIB) today and set a price target of $335. The company’s shares opened today at $299.39.
According to TipRanks.com, Kulkarni is a 3-star analyst with an average return of 3.5% and a 51.4% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Intra-Cellular Therapies, and Alder Biopharmaceuticals.
Biogen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $340.95.
See today’s analyst top recommended stocks >>
Based on Biogen Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $1.17 billion. In comparison, last year the company had a net profit of $748 million.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BIIB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
